PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 09/30/2011) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
78973484 |
LAW OFFICE ASSIGNED |
LAW OFFICE 101 |
MARK SECTION |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
APLEVANT |
OWNER SECTION (current) |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317 651 1346 |
FAX |
317 276 1919 |
OWNER SECTION (proposed) |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317 651 1346 |
FAX |
317 276 1919 |
EMAIL |
XXXX |
ATTORNEY SECTION (current) |
NAME |
Bruce W. Longbottom |
FIRM NAME |
ELI LILLY AND COMPANY |
STREET |
LILLY CORPORATE CTR |
CITY |
INDIANAPOLIS |
STATE |
Indiana |
POSTAL CODE |
46285-0001 |
COUNTRY |
United States |
PHONE |
317 651 1346 |
FAX |
317 276 1919 |
EMAIL |
trademarks@lilly.com |
ATTORNEY DOCKET NUMBER |
15726 |
ATTORNEY SECTION (proposed) |
NAME |
Bruce W. Longbottom |
FIRM NAME |
ELI LILLY AND COMPANY |
STREET |
LILLY CORPORATE CTR |
CITY |
INDIANAPOLIS |
STATE |
Indiana |
POSTAL CODE |
46285-0001 |
COUNTRY |
United States |
PHONE |
317 651 1346 |
FAX |
317 276 1919 |
EMAIL |
trademarks@lilly.com |
AUTHORIZED TO COMMUNICATE VIA E-MAIL |
Yes |
ATTORNEY DOCKET NUMBER |
15726 |
OTHER APPOINTED ATTORNEY |
Robert E. Lee, Jr., Douglas K. Norman, Lawrence T. Welch |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal
diseases and disorders, blood diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, diabetes, diabetic neuropathy, endocrine diseases and disorders,
gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders,
neurodegenerative diseases and disorders, neurological disorders, obesity, ophthalmologic conditions and diseases, pain, peripheral nervous system diseases and disorders, reproductive system diseases
and disorders, sexual dysfunction, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; pharmaceutical preparations for the prevention of diabetes;
antipsychotic agents; and antidepressants |
GOODS OR SERVICES DELETED FROM THE APPLICATION OR INCLUDED IN A SEPARATE STATEMENT OF USE AND REQUEST TO DIVIDE |
diabetic neuropathy, ophthalmologic conditions and diseases, peripheral nervous system diseases and disorders, pharmaceutical
preparations for the prevention of diabetes; agents; |
GOODS OR SERVICES FOR WHICH APPLICANT HAS BONA FIDE INTENTION TO USE |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal
diseases and disorders, blood diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal
diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases
and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders;
antipsychotics and antidepressants |
EXTENSION SECTION |
EXTENSION NUMBER |
3 |
ONGOING EFFORT |
product or service research development |
ALLOWANCE MAIL DATE |
04/17/2007 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT |
150 |
TOTAL AMOUNT |
150 |
SIGNATURE SECTION |
SIGNATURE |
/blongbottom/ |
SIGNATORY'S NAME |
Bruce W. Longbottom |
SIGNATORY'S POSITION |
Associate General Counsel |
DATE SIGNED |
10/02/2008 |
FILING INFORMATION |
SUBMIT DATE |
Thu Oct 02 17:06:49 EDT 2008 |
TEAS STAMP |
USPTO/ESU-XX.X.XX.XX-2008
1002170649644653-78973484
-400889ae2fac2ccfc62f1298
c236ebcb839-DA-2318-20081
002122102376325 |
PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 09/30/2011) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: APLEVANT
SERIAL NUMBER: 78973484
The applicant, Eli Lilly and Company, having an address of Lilly Corporate Center, Indianapolis, Indiana United States 46285, requests a six-month extension of time to file the Statement of Use under
37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 04/17/2007.
For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal diseases and disorders, blood diseases
and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, diabetes, diabetic neuropathy, endocrine diseases and disorders, gastrointestinal diseases and
disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and
disorders, neurological disorders, obesity, ophthalmologic conditions and diseases, pain, peripheral nervous system diseases and disorders, reproductive system diseases and disorders, sexual
dysfunction, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; pharmaceutical preparations for the prevention of diabetes; antipsychotic agents; and
antidepressants
This filing does
NOTcover the following goods or services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods or services
are either being
permanently deleted or included in a separately filed Request to Divide: diabetic neuropathy, ophthalmologic conditions and diseases, peripheral nervous system diseases and
disorders, pharmaceutical preparations for the prevention of diabetes; agents;
The applicant has a continued bona fide intention to use or use through the applicant's related company or licensee the mark in commerce on or in connection with the following goods or services
listed in the Notice of Allowance or as subsequently modified for this specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders,
anxiety, bone and skeletal diseases and disorders, blood diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, diabetes, endocrine diseases and
disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders,
neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic
diseases and disorders; antipsychotics and antidepressants
This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods and/or services covered by
the extension request: product or service research development
The applicant hereby appoints Bruce W. Longbottom and Robert E. Lee, Jr., Douglas K. Norman, Lawrence T. Welch of ELI LILLY AND COMPANY, LILLY CORPORATE CTR, INDIANAPOLIS, Indiana United States
46285-0001 to submit this Request for Extension of Time to File a Statement of Use on behalf of the applicant. The attorney docket/reference number is 15726.
A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
Declaration
The undersigned being hereby warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false statements
and the like may jeopardize the validity of this document, declares that he/she is properly authorized to execute this document on behalf of the Owner; and all statements made of his/her own
knowledge are true and that all statements made on information and belief are believed to be true.
Signature: /blongbottom/ Date Signed: 10/02/2008
Signatory's Name: Bruce W. Longbottom
Signatory's Position: Associate General Counsel
Mailing Address:
ELI LILLY AND COMPANY
LILLY CORPORATE CTR
INDIANAPOLIS, Indiana 46285-0001
Mailing Address:
ELI LILLY AND COMPANY
LILLY CORPORATE CTR
INDIANAPOLIS, Indiana 46285-0001
RAM Sale Number: 2318
RAM Accounting Date: 10/03/2008
Serial Number: 78973484
Internet Transmission Date: Thu Oct 02 17:06:49 EDT 2008
TEAS Stamp: USPTO/ESU-XX.X.XX.XX-2008100217064964465
3-78973484-400889ae2fac2ccfc62f1298c236e
bcb839-DA-2318-20081002122102376325